SERINA THERAPEUTICS INC. (SER) Stock Price & Overview
NYSEARCA:SER • US81751A1088
Current stock price
The current stock price of SER is 2.61 USD. Today SER is down by -13.86%. In the past month the price increased by 44.2%. In the past year, price decreased by -50.66%.
SER Key Statistics
- Market Cap
- 27.823M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.51
- Dividend Yield
- N/A
SER Stock Performance
SER Stock Chart
SER Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to SER. When comparing the yearly performance of all stocks, SER is a bad performer in the overall market: 86.78% of all stocks are doing better.
SER Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SER. SER scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SER Earnings
On March 23, 2026 SER reported an EPS of -0.27 and a revenue of -10.00K. The company beat EPS expectations (41.89% surprise).
SER Forecast & Estimates
6 analysts have analysed SER and the average price target is 13.26 USD. This implies a price increase of 408.05% is expected in the next year compared to the current price of 2.61.
For the next year, analysts expect an EPS growth of -34.1% and a revenue growth 134.46% for SER
SER Groups
Sector & Classification
SER Financial Highlights
Over the last trailing twelve months SER reported a non-GAAP Earnings per Share(EPS) of -1.51. The EPS increased by 88.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -89.75% | ||
| ROE | -633.01% | ||
| Debt/Equity | 0 |
SER Ownership
SER Latest News, Press Relases and Analysis
SER Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.23 | 366.329B | ||
| AMGN | AMGEN INC | 15.47 | 190.793B | ||
| GILD | GILEAD SCIENCES INC | 15.49 | 171.639B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.41 | 115.576B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.19 | 79.234B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.98 | 43.592B | ||
| INSM | INSMED INC | N/A | 31.968B | ||
| NTRA | NATERA INC | N/A | 27.973B | ||
| BIIB | BIOGEN INC | 11.88 | 27.764B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.83 | 23.738B | ||
| MRNA | MODERNA INC | N/A | 21.145B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.686B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SER
Company Profile
Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. The company is headquartered in Huntsville, Alabama and currently employs 12 full-time employees. The company went IPO on 2018-11-29. The firm's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Company Info
IPO: 2018-11-29
SERINA THERAPEUTICS INC.
601 Genome Way,, Suite 2001
Huntsville ALABAMA US
Employees: 12
Phone: 12563279630
SERINA THERAPEUTICS INC. / SER FAQ
What does SER do?
Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. The company is headquartered in Huntsville, Alabama and currently employs 12 full-time employees. The company went IPO on 2018-11-29. The firm's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Can you provide the latest stock price for SERINA THERAPEUTICS INC.?
The current stock price of SER is 2.61 USD. The price decreased by -13.86% in the last trading session.
Does SERINA THERAPEUTICS INC. pay dividends?
SER does not pay a dividend.
What is the ChartMill rating of SERINA THERAPEUTICS INC. stock?
SER has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting SER stock to perform?
6 analysts have analysed SER and the average price target is 13.26 USD. This implies a price increase of 408.05% is expected in the next year compared to the current price of 2.61.
What is the market capitalization of SER stock?
SERINA THERAPEUTICS INC. (SER) has a market capitalization of 27.82M USD. This makes SER a Nano Cap stock.
When does SERINA THERAPEUTICS INC. (SER) report earnings?
SERINA THERAPEUTICS INC. (SER) will report earnings on 2026-03-30, after the market close.